When reviewing the financing leads that occurred in January 2018, GlobalData has determined that more financing leads occurred and more funding for biopharmaceutical companies was secured in January compared to the same period of last year.

According to the GlobalData’s Lead Sheet, more than 132 financing leads worth $11.72B occurred in January 2018, which is a considerable improvement over the 66 financing leads worth $2.06B that occurred in January 2017.  A breakdown of those leads based on type and amount raised can be seen in Figures 1 and 2.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Figure 1: Number of financing leads by type.

Figure 2: Amount of financing raised by type in USD millions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

 

Upon further analysis of the charts, it is apparent that there was more than a 50% increase in the amount of each financing type in January 2018 compared to January 2017, including venture capital investments, secondary public offerings, and other types such as grants, initial public offerings (IPOs) that were filed and completed, milestone payments, and private debt and equity placements.

It is also worth noting that in both January 2017 and 2018, there were fewer secondary public offering financing leads than other types, but secondary public offerings raised more money than other types.

As this review only compared January 2017 and 2018, it has shown just a small trend in the possible funding for biopharmaceutical companies in 2018. If this trend continues, GlobalData believes that secondary public offerings will continue to raise the most money in 2018.